ECE2023 Eposter Presentations Diabetes, Obesity, Metabolism and Nutrition (355 abstracts)
Real-world effectiveness analysis of oral versus subcutaneous semaglutide in patients with type 2 diabetes mellitus
Juan Carlos Ferrer Garcia 1 , Raquel Albalat-Galera 1 , Victor Atienza Moya 2 , Jessica Sanchez Hernandez 3 , Luis Arribas Palomar 1 , Ignacio Ramos Casamayor 1 , Ana Artero Fullana 1 , Cintia Gonzalez Blanco 1 , Ana Jiménez Portilla 1 & Carlos Sánchez Juan 1
1University General Hospital of Valencia, Endocrinology, Diabetes and Nutrition, Valencia, Spain; 2General Hospital of Requena, Endocrinology, Diabetes and Nutrition, Requena, Spain; 3Medical Center of Picassent, Primary Care, Picassent, Spain
Background and Objective: Semaglutide, a glucagon-like peptide 1 (GLP1a) receptor agonist, reduces the risk of major adverse cardiovascular events in patients with type 2 diabetes mellitus (DM2). An oral version of semaglutide is now available, and patients may prefer it to the subcutaneous form. Our objective was to compare the effectiveness and safety of both formulations in real life.
Methods: Retrospective real-world efficacy analysis including aGLP1-naïve adults with T2DM who were started on oral or subcutaneous semaglutide add-on to T2DM treatment during the year 2022. The primary outcome was change in HbA1c. Secondary outcomes were changes in weight and lipid profile, occurrence of gastrointestinal side effects (GSEs), and discontinuations. Linear mixed models were used to estimate changes in HbA1c, weight, and BMI, and logistic regression was used to analyze GSEs and discontinuations.
Results: 136 patients were included, 82 in the subcutaneous semaglutide group and 54 in the oral semaglutide group. Mean age was 60 years (SD 1.5) and HbA1c 8.2% (SD 0.2). At 24 weeks, the mean reductions in HbA1c were: -1.2% (SD 0.2) with subcutaneous semaglutide and -1.3% (SD 0.2) for oral semaglutide (p n.s). The mean changes in body weight from baseline to week 24 were: -5.5 kg (SE 2.3) for subcutaneous semaglutide and -6.9 kg (SD 2.4) for oral semaglutide, (p n.s ). There were no differences in the lipid profile. Some type of adverse event occurred in 41 patients in the subcutaneous semaglutide group (50%) and in 21 patients in the oral semaglutide group (39%), mostly mild gastrointestinal effects. There were 11 withdrawals from treatment in the subcutaneous semaglutide group (13.4%) and 5 in the oral semaglutide group (9.2%).
Conclusion: Semaglutide, in its two presentations (subcutaneous and oral) are effective in the treatment of patients with DM2. There were no differences in HbA1c, weight, or lipid profile, or in the appearance of adverse effects or dropouts.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more